Two diabetes drug companies have signed a deal to joint develop and license an emerging treatment for diabetes and obesity .
The deal, between pharmaceutical company AstraZeneca and biotechnological innovator Biocompatibles, sent shares in the latter company rocketing.
The agreement will see the development of the GLP-1 ananlogue, which was created by a subsidiary of Biocompatibles, Cellmed. Cellmed is to manage all pre-clinical trials, whilst AstraZeneca cover the cost of product development.
Chief Executive of Biocompatibles, Crispin Simo, reportedly commented: “A product development agreement with AstraZeneca in the field of diabetes and obesity is a significant event for Biocompatibles and further evidence of the value being created by CellMed. This programme is now a high strategic and operational priority. We are delighted to adopt the licensing model with a company of AstraZeneca’s drug development and marketing capabilities.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…